IL-18 enhances the migration ability of murine melanoma cells through the generation of ROI and the MAPK pathway

Immunology Letters

Volumn 107, Issue 2, 2006, Pages 125-130

  Jung, Min Kyung ^a   Song, Hyun Keun ^b   Kim, Kyung Eun ^a   Hur, Dae Young ^b   Kim, Taesung ^c   Bang, Saic ^d   Park, Hyunjeong ^e   Cho, Dae Ho ^a  

^a Sookmyung Women's University   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Korea University   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e The Catholic University of Korea   (South Korea)

Author keywords

IL 18; MAPK; Melanoma; Migration; ROI

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACETYLCYSTEINE; COMPLEMENTARY DNA; INTERLEUKIN 18; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; GENETIC TRANSFECTION; INFLAMMATORY INFILTRATE; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN TUMOR;

ACETYLCYSTEINE; ANIMALS; CELL MOVEMENT; FLAVONOIDS; FREE RADICAL SCAVENGERS; INTERLEUKIN-18; MELANOMA, EXPERIMENTAL; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES; TRANSFECTION;

EID: 33751180075     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2006.08.004     Document Type: Article

References (34)

1. Mancianti M.L., and Herlyn M. Tumor progression in melanoma: the biology of epidermal melanocytes in vitro. Carcinog Compr Surv 11 (1989) 369-386
2. Huber D., Philipp J., and Fontana A. Protease inhibitors interfere with the transforming growth factor-b-dependent but not the transforming growth factor b-independent pathway of tumor cell mediated immunosuppression. J Immunol 148 (1992) 277-284
3. Mukherji B., and Chakraborty N.G. Immunobiology an immunotherapy of melanoma. Curr Opin Oncol 7 (1995) 175-184
4. Ferrone S., and Marincola F.M. Loss of HLA class I antigens by Melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunology 16 (1995) 487-494
5. Hahne M., Rimoldi D., Schroter M., Romero P., Schreiter M., French L.E., et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274 (1996) 1363-1366
6. Okamura H., Tsutsui H., Komatsu T., Yustudo M., Hakura A., Tanimoto T., et al. Cloning of a new cytokine that induces IFN-r production by T cells. Nature 378 (1995) 88-91
7. Golab J. Interleukin 18-IFN-r inducing factor-a novel player in tumor immunotheraphy?. Cytokine 12 (2000) 332-338
8. Zang T., Kwakani K., Qureshi M.H., Okamura H., Kurimoto M., and Saito A. Interleukin-12 (IL-12) and IL-18 synergistically induced the fungicidal activity of murine peritoneal exudates cells against Cryptococcus neoformans through production of interferone by natural killer cells. Infect Immune 65 (1997) 3594-3599
9. Stoll S., Muller G., Kurimoto M., Saloga J., Tanimoto T., Yamauchi H., et al. Production of IL-18 (IFN-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol 159 (1997) 298-302
10. Kampfer H., Muhl H., Manderscheid M., Kalina U., Kauschat D., Pfeilschifter J., et al. Regulation of interleukin-18 (IL-18) expression in keratinocytes (HaCaT): implications for early woundhealing. Cytokine Netw 11 (2000) 626-633
11. Conti B., Jahng J.W., Tinti C., Son J.H., and Joh T.H. Induction of interferon-c inducing factor in the adrenal cortex. J Biol Chem 272 (1997) 2035-2037
12. Cho D., Song H., Kim Y.M., Houh D., Hur D.Y., Park H., et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 60 (2000) 2703-2709
13. Park H., Byun D., Kim T.S., Kim Y.I., Kang J.S., Hahm E.S., et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett 79 (2001) 215-219
14. Vidal-Vanaclocha F., Fantuzzi G., Mendoza L., Fuentes A.M., Anasagasti M.J., Martin J., et al. IL-18 regulates IL-1b-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci 97 (2000) 734-739
15. Frank E., Theodore L., Drell I.V., Kerstin L., Jan J., and Kurt S.Z. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 5 (2004) 254-258
16. Bar E.M. Molecular mechanisms of melanoma metastasis. J Cell Physiol 173 (1997) 275-278
17. Park C.C., Morel J.C., Amin M.A., Connors M.A., Harlow L.A., and Koch A.E. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167 (2001) 1644-1653
18. Puren A.J., Fantuzzi G., Gu Y., Su M.S., and Dinarello C.A. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 101 (1998) 711-721
19. Kohka H., Yoshino T., Iwagaki H., Sakuma I., Tanimoto T., Matsuo Y., et al. Interleukin-18/interferon-gamma-inducing factor, a novel cytokine, up-regulates ICAM-1 (CD54) expression in KG-1 cells. J Leukoc Biol 64 (1998) 519-527
20. Obata N.H., Tamakoshi K., Shibata K., et al. Effect of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 17 (1997) 337-342
21. Pan W., Zadina J.E., Harlan R.E., Weber J.T., Banks W.A., and Kastin A.J. Tumor necrosis factor-α: a neuromodulator in the CNS. Neurosci Biobehav Rev 21 (1997) 603-613
22. Shohami E., Ginis I., and Hallenbeck J.M. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 10 (1999) 119-130
23. Cho D., Kang J.S., Park J.H., Kim Y.I., Hahm E., Lee J.C., et al. The enhanced IL-18 production by UVB irradiation requires ROIand AP-1 signaling in human keratinocyte cell line (HaCaT). Biochem Biophys Res Commun 298 (2002) 289-295
24. Mendoza L., Carrascal T., De Luca M., Fuentes A.M., Salado C., Blanco J., et al. Hydrogen peroxide mediates vascular cell adhesion molecule-1 expression from interleukin-18-activated hepatic sinusoidal endothelium: implications for circulating cancer cell arrest in the murine liver. Hepatology 34 (2001) 298-310
25. Cerutti P.A. Pro-oxidant states and tumor promotion. Science 227 (1985) 375-381
26. Brown N.S., and Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 3 (2001) 323-327
27. Widmann C., Gibson S., Jarpe M.B., and Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79 (1999) 143-180
28. Kampen G.T., Stafford S., Adachi T., Jinquan T., Quan S., Grant J.A., et al. Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 95 (2000) 1911-1917
29. Boehme S.A., Sullivan S.K., Crowe P.D., Santos M., Conlon P.J., Sriramarao P., et al. Activation of mitogen-activated protein kinase regulates eotaxin-induced eosinophil migration. J Immunol 163 (1999) 1611-1618
30. Hue J., Kim A., Song H., Choi I., Park H., Kim T., et al. IL-18 enhances SCF production of melanoma cells by regulating ROI and p38 MAPK activity. Immunol Lett 96 (2005) 211-217
31. Smalley K.S. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer 104 (2003) 527-532
32. Zhuang L., Lee C.S., Scolyer R.A., McCarthy S.W., Palmer A.A., Zhang X.D., et al. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 58 (2005) 1163-1169
33. - in vascular smooth muscle cells. Circ Res 77 (1995) 29-36
34. Kefaloyianni E., Gaitanaki C., and Beis I. ERK1/2 and p38-MAPK signaling pathways, through MSK1, are involved in NF-kappaB transactivation during oxidative stress in skeletal myoblasts. Cell Signal June (2006)